Filing summary
Entity and period: The request identifies Tectonic Therapeutic, Inc., but the supplied filing is AVROBIO, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed March 16, 2020. This summary reflects the supplied AVROBIO filing, not a Tectonic filing. The filing reports annual results, not a standalone 2019 fourth quarter.
Business context
AVROBIO was a clinical-stage gene therapy company developing ex vivo lentiviral therapies for rare diseases. Its pipeline included AVR-RD-01 for Fabry disease, AVR-RD-04 for cystinosis, AVR-RD-02 for Gaucher disease and preclinical AVR-RD-03 for Pompe disease. The company had no approved products and had generated no product revenue.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $55.0 million | $35.1 million |
| General and administrative expense | $20.8 million | $11.1 million |
| Total operating expenses | $75.8 million | $46.2 million |
| Net loss | $73.0 million | $46.4 million |
| Net loss per share, basic and diluted | $2.66 | $3.62 |
| Net cash used in operating activities | $67.7 million | $37.6 million |
| Capital expenditures | $1.6 million | $1.8 million |
- At December 31, 2019, cash and cash equivalents were $187.0 million; current assets were $195.7 million and current liabilities were $14.0 million. Total assets were $200.5 million, total liabilities $14.5 million and stockholders’ equity $186.0 million.
- The company reported no outstanding borrowings at year-end. A prior $10 million loan facility expired in 2018 without being drawn.
- In July 2019, AVROBIO raised approximately $129.5 million net from a follow-on stock offering. A subsequent February 2020 offering raised approximately $93.5 million net. Management estimated that year-end cash plus the February proceeds would fund operating and capital needs into the second quarter of 2022; this is a forward-looking estimate, not a guarantee.
- Operating cash use increased by about $30.0 million year over year, while net loss increased by $26.6 million. The company remained dependent on external financing and anticipated additional spending as development advanced.
- Interest income was $2.9 million in 2019 versus $1.7 million in 2018. No meaningful operating margins can be assessed because the company had no product revenue.
Material changes and operating developments
- Operating expenses rose 64% year over year, driven by increased R&D spending, hiring, facilities costs and public-company expenses. Pompe and cystinosis program spending increased substantially; Fabry and Gaucher direct program costs declined.
- AVROBIO introduced its “plato” platform, including a proprietary four-plasmid vector, closed automated manufacturing and busulfan conditioning with therapeutic drug monitoring. The fourth patient in the Fabry Phase 2 trial was the first treated using the platform in December 2019.
- By March 6, 2020, four patients had been dosed in the company-sponsored Fabry Phase 2 trial; five had been dosed in the investigator-sponsored Fabry Phase 1 trial. One patient had been dosed in the cystinosis Phase 1/2 trial. Gaucher trial enrollment had started, with first dosing expected in Q2 2020; Pompe remained preclinical.
- Early clinical observations included an 87% reduction in kidney Gb3 inclusions at 12 months in the first Fabry Phase 2 patient, and reduced granulocyte cystine in the first cystinosis patient at three months. These are small-sample, preliminary findings and do not establish efficacy or durability.
Outlook, risks and unusual items
- Management expected significant losses and expenses to continue for the foreseeable future and did not provide revenue or profitability guidance.
- Key risks include clinical failure or adverse events, limited patient enrollment, regulatory and comparability requirements for the new platform, manufacturing and third-party supplier dependence, competition, reimbursement uncertainty, and the need to raise additional capital.
- Busulfan conditioning may cause toxicity; the filing describes transient neutrophil and platelet suppression and other expected side effects. Long-term safety and therapeutic durability remain uncertain.
- The filing specifically identifies the COVID-19 outbreak as a potential source of clinical-trial, staffing, travel and supply-chain disruption; the extent of impact was uncertain at filing.
- Management concluded that disclosure controls were not effective at year-end 2019. Previously identified material weaknesses in financial close, complex accounting, expense classification, R&D accruals and cash disbursements were not fully remediated, although remediation efforts continued. The auditor gave an unqualified opinion on the financial statements but did not opine on internal control effectiveness.
- No material litigation was reported. The company disclosed $3.1 million of future minimum operating lease payments as of year-end, plus contingent milestone and royalty obligations under license agreements.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-K is for AVROBIO, Inc., not Tectonic Therapeutic, Inc.
- Review subsequent clinical disclosures, especially patient follow-up, adverse events, enrollment progress and evidence supporting efficacy and durability.
- Assess actual cash use against the stated runway through Q2 2022, including the impact of the February 2020 offering and planned program spending.
- Track remediation and testing of internal controls, given the disclosed unremediated material weaknesses and ineffective disclosure controls.
- Evaluate whether the plato platform, busulfan conditioning and outsourced manufacturing can be consistently implemented and accepted by regulators.
- Consider potential dilution from future equity financing and stock-based awards; the company stated it did not expect to pay dividends.